{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:45:57Z","timestamp":1754145957143,"version":"3.41.2"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,10]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Current research on antiviral treatment in children is relatively limited, especially in children under 1 year old.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Liu XX, an 8-month-old infant (case number: 3001120473), presented to the hospital in August 2016 with a chief complaint of being \u201chepatitis B surface antigen positive for 8 months and experiencing abnormal liver function for 5 months.\u201d<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed as chronic hepatitis B cirrhosis (G3S3-4) with active compensatory phase.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The treatment regimen commenced with lamivudine (LAM) for the initial 8 weeks, followed by the addition of interferon \u03b1 (IFN\u03b1) after 1 year of age. At 2 years old, LAM was substituted with entecavir, and at 3 years old, IFN\u03b1 was replaced with pegylated interferon \u03b1 (PEG IFN\u03b1).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 8 weeks of LAM monotherapy, Liu XX experienced hepatitis B e antigen loss. Subsequently, after 36 weeks of IFN\u03b1 add-on therapy, hepatitis B virus DNA became undetectable, and after 48 weeks of switching to PEG IFN\u03b1 treatment, hepatitis B surface antigen loss was observed. Remarkably, following 50 weeks of drug discontinuation, the child remained functionally cured.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Chronic hepatitis B virus-infected infants and young children can achieve durable functional cure with PEG IFN\u03b1-based individualized therapy. This case provides a valuable reference for the diagnosis and treatment of such patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041103","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T15:03:01Z","timestamp":1736521381000},"page":"e41103","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Functional cure of a young child with chronic hepatitis B cirrhosis treated by pegylated interferon \u03b1 combination therapy: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Yu","family":"Gan","sequence":"first","affiliation":[{"name":"Pediatric Hepatology, Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9917-9466","authenticated-orcid":false,"given":"Hongfei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jumei Doctor Group Medical (Shenzhen) Co., Ltd, Shenzhen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl. 1","key":"R1-20250717","first-page":"S24","article-title":"Functional cure based on pegylated interferon \u03b1-2b therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China)-4 years data update.","volume":"76","author":"Mo","year":"2022","journal-title":"Hepatology"},{"issue":"S1","key":"R2-20250717","doi-asserted-by":"crossref","first-page":"S1145","DOI":"10.1016\/S0168-8278(23)03277-4","article-title":"Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection, a systematic review.","volume":"78","author":"Gielen","year":"2023","journal-title":"J Hepatol"},{"key":"R3-20250717","doi-asserted-by":"crossref","first-page":"405","DOI":"10.14218\/JCTH.2021.00142","article-title":"Clinical predictors of functional cure in children 1-6 years-old with chronic hepatitis B.","volume":"10","author":"Pan","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"R4-20250717","doi-asserted-by":"crossref","first-page":"102728","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"key":"R5-20250717","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/jvh.13372","article-title":"De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis.","volume":"27","author":"Dong","year":"2020","journal-title":"J Viral Hepat"},{"key":"R6-20250717","first-page":"888","article-title":"The guideline of prevention and treatment for chronic hepatitis B: a 2015 update.","volume":"23","author":"Hou","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"R7-20250717","article-title":"Supplement approval: fulfilment of postmarketing requirement."},{"key":"R8-20250717","article-title":"Pegasys: summary of opinion (post authorisation)."},{"key":"R9-20250717","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3201\/eid2305.161477","article-title":"Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China.","volume":"23","author":"Cui","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"R10-20250717","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(03)15108-2","article-title":"Viral hepatitis B.","volume":"362","author":"Lai","year":"2003","journal-title":"Lancet"},{"key":"R11-20250717","first-page":"570","article-title":"A retrospective study on pathological and clinical characteristics of 3 932 children with liver diseases.","volume":"52","author":"Zhang","year":"2014","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"R12-20250717","first-page":"738","article-title":"A retrospective study on HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B aged 1-7 years.","volume":"24","author":"Zhu","year":"2016","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"R13-20250717","first-page":"1268","article-title":"Value of transient elastography in the diagnosis of liver fibrosis in chronic hepatitis B children of different ages.","volume":"36","author":"Xu","year":"2020","journal-title":"J Clin Hepatol"},{"key":"R14-20250717","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijid.2022.08.017","article-title":"Liver histology of treatment-na\u00efve children with chronic hepatitis B virus infection in Shanghai China.","volume":"123","author":"Hu","year":"2022","journal-title":"Int J Infect Dis"},{"key":"R15-20250717","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"R16-20250717","first-page":"1309","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022).","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"R17-20250717","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jvh.12007","article-title":"Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon?","volume":"20","author":"Poddar","year":"2013","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"R18-20250717","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jvh.13165","article-title":"Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B.","volume":"26","author":"Fan","year":"2019","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"R19-20250717","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/jvh.13154","article-title":"Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B.","volume":"26","author":"Liu","year":"2019","journal-title":"J Viral Hepat"},{"key":"R20-20250717","first-page":"S82","article-title":"Antiviral effect and clinical predictors of HBsAg seroconversion in children aged 1-6 years old with chronic hepatitis B Virus Infection.","volume":"14","author":"Zhu","year":"2020","journal-title":"Hepatol Int"},{"key":"R21-20250717","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2019.06.009","article-title":"Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B.","volume":"71","author":"Zhu","year":"2019","journal-title":"J Hepatol"},{"key":"R22-20250717","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/hep.30050","article-title":"Efficacy and safety of peginterferon Alfa-2a (40KD) in children with chronic hepatitis B: the PEG-B-ACTIVE study.","volume":"68","author":"Wirth","year":"2018","journal-title":"Hepatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T20:00:50Z","timestamp":1752782450000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041103","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,1,10]]}}}